Klebsiella pneumoniae

Overview

Klebsiella pneumoniae is a Gram-negative, encapsulated bacterium in the family Enterobacteriaceae and a clinically important opportunistic pathogen. It is best known for causing healthcare-associated and community-acquired infections, including pneumonia, bloodstream infection, urinary tract infection, and other invasive infections, particularly in individuals with underlying illness or impaired host defenses. Its pathogenic success is supported by traits such as capsule production, adherence, and the ability to form biofilms, all of which can contribute to persistence in host tissues and on medical devices.

From a biomedical perspective, Klebsiella pneumoniae is also a major target in antimicrobial resistance research. It is frequently studied alongside related pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli because it can acquire resistance to β-lactam antibiotic classes, including carbapenems and piperacillin-tazobactam. Recent work has focused on rapid detection methods, mechanistic studies of resistance and immune evasion, and anti-biofilm or antimicrobial approaches designed to suppress multidrug-resistant strains.

Recent Publications Summary

• A spectroscopic study used surface-enhanced Raman scattering (SERS) combined with supervised machine learning and explainable artificial intelligence to discriminate five clinically relevant pathogens, including Klebsiella pneumoniae, and to infer differences in pathogenicity from a biomarker perspective 42422903Jul. This work placed K. pneumoniae in a comparative framework with Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), and Enterococcus faecalis, emphasizing pathogen classification rather than therapeutic intervention.

• A designed antimicrobial peptide, APH143, showed potent activity against common clinical pathogens including Klebsiella pneumoniae, P. aeruginosa, A. baumannii, and S. aureus, with minimum inhibitory concentration values of 2–4 μg/mL and low hemolytic activity 41921827Apr. The study highlighted imperfectly amphipathic α-helical peptide design as a strategy for balancing antimicrobial potency and toxicity.

• Co-encapsulation of formic acid and Satureja hortensis essential oil was reported to enhance antibacterial activity against Klebsiella pneumoniae as well as Salmonella enterica, Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli 42302970Jun. The formulation was assessed by disk diffusion, MIC, and MBC assays, supporting its broad in vitro antibacterial potential.

• A nanoemulsion-based strategy was investigated for suppression of multidrug-resistant Klebsiella pneumoniae through reduction of oxygen consumption and inhibition of biofilm formation 42530666Jul. The study evaluated reference strains and clinical multidrug-resistant Klebsiella isolates, indicating interest in both standard laboratory strains and clinically derived resistant organisms.

• Microfluidics-enabled proteomic profiling was used to study iron-driven immune evasion by an antimicrobial-resistant pathogen, with a label-free microfluidic chip developed to reproducibly separate Klebsiella pneumoniae from murine macrophages during co-culture for high-resolution proteomic analysis 41916300Mar. This approach linked K. pneumoniae biology to host-pathogen interaction studies and proteome-level analysis of immune evasion.

• Green-synthesized selenium nanoparticles were tested for antimicrobial and antibiofilm effects against multiple organisms, including Klebsiella pneumoniae, Staphylococcus aureus, Escherichia coli, Citrobacter freundii, and Candida albicans 42143081May. In this context, K. pneumoniae served as one of several assay organisms used to evaluate broad-spectrum antimicrobial and biofilm-inhibitory activity.

• A study on piperacillin-tazobactam resistance in Klebsiella pneumoniae reported that resistance is often associated with IS26-mediated blaSHV-1 amplification in a widespread Klebsiella-adapted plasmid 41874364Mar. This work focused on the genetic basis of β-lactam antibiotic resistance and underscored the importance of mobile genetic elements and gene amplification in resistance phenotypes.

• An extraction-free HLPCR-Cas12a assay was developed for ultra-sensitive and rapid detection of Acinetobacter baumannii and Klebsiella pneumoniae following craniotomy, reflecting the clinical need for fast identification of common drug-resistant pathogens in postoperative settings 41905499Mar. The study emphasized point-of-care–oriented molecular diagnostics rather than treatment, with K. pneumoniae included as a target organism alongside A. baumannii.

What Changes, What Holds

1. SERS plus machine learning adds a diagnostic classification route for K. pneumoniae
METHOD Surface-enhanced Raman scattering paired with supervised machine learning and explainable AI changes how K. pneumoniae is being studied: it supports pathogen discrimination and biomarker-level interpretation rather than treatment or pathogenesis claims. The baseline already emphasized rapid detection methods, and this work fits that direction by strengthening spectral, data-driven identification frameworks. It does not alter the established view of K. pneumoniae as an opportunistic pathogen; it mainly broadens the analytical toolkit used to recognize it 42422903Jul.

2. APH143 supports peptide-based broad-spectrum anti-Klebsiella development
REINFORCES APH143 adds another example of an antimicrobial peptide with activity against K. pneumoniae, aligning with the baseline’s emphasis on anti-biofilm and antimicrobial approaches against multidrug-resistant strains. Its main significance is not a new biological role for the bacterium, but confirmation that rational peptide design can retain potency while limiting toxicity across clinically important pathogens. The finding sharpens a therapeutic strategy already under active study rather than revising the organism’s known behavior 41921827Apr.

3. Co-encapsulation broadens nontraditional in vitro antibacterial options against K. pneumoniae
REINFORCES Formic acid plus Satureja hortensis essential oil extends the established theme of suppressing K. pneumoniae with anti-infective formulations. The work does not challenge the baseline account; it supports the idea that the organism remains vulnerable to chemically diverse in vitro approaches, including combination and delivery strategies. Its contribution is practical rather than conceptual, reinforcing interest in broad antibacterial screening and formulation-based activity against a pathogen already known for persistence and resistance 42302970Jun.

4. Nanoemulsion suppression of resistant K. pneumoniae adds another anti-biofilm resistance-control strategy
REINFORCES Nanoemulsion-mediated reduction of oxygen consumption and biofilm inhibition fits squarely within the baseline’s focus on multidrug-resistant K. pneumoniae and anti-biofilm interventions. The work strengthens, rather than changes, the view that dispersal of biofilm-associated physiology is a plausible route to control resistant strains. Its importance lies in mechanism-guided suppression of established virulence-associated behavior, not in redefining the organism’s role or overturning known resistance patterns 42530666Jul.

5. Microfluidic proteomics opens a host-interaction window on iron-driven immune evasion
METHOD A label-free microfluidic separation platform changes how K. pneumoniae–macrophage interactions are studied, enabling higher-resolution proteomic analysis of immune evasion. The baseline already notes mechanistic studies of immune evasion, and this work advances the measurement approach rather than the biological conclusion. It therefore belongs as a methodological refinement that could make host-pathogen studies more reproducible and informative, especially for antimicrobial-resistant organisms 41916300Mar.

6. selenium nanoparticles add another broad in vitro antimicrobial and antibiofilm screen
REINFORCES Green-synthesized selenium nanoparticles join the existing collection of anti-K. pneumoniae agents evaluated for antimicrobial and antibiofilm effects. The paragraph does not establish a new role for the bacterium; it confirms that K. pneumoniae remains a useful assay organism for testing broad-spectrum nanomaterial activity. This is consistent with the baseline’s description of ongoing anti-biofilm and antimicrobial research, and it adds practical screening evidence rather than a conceptual shift 42143081May.

7. IS26-linked blaSHV-1 amplification clarifies a specific route to piperacillin-tazobactam resistance
REINFORCES IS26-mediated blaSHV-1 amplification strengthens the baseline’s statement that K. pneumoniae can acquire resistance to β-lactams, including piperacillin-tazobactam. Rather than contradicting the overview, it specifies one genetic mechanism by which resistance can emerge in a Klebsiella-adapted plasmid background. The key advance is mechanistic precision: resistance is not just present, but appears tied to mobile element-driven gene amplification in clinically relevant lineages 41874364Mar.

8. HLPCR-Cas12a adds rapid postoperative detection of K. pneumoniae to point-of-care diagnostics
METHOD Extraction-free HLPCR-Cas12a advances the baseline’s rapid detection theme by providing a fast molecular assay for postoperative identification of K. pneumoniae alongside A. baumannii. The finding changes how the organism is detected, not what it is or how it causes disease. Its significance is clinical workflow: quicker recognition of drug-resistant pathogens after craniotomy could improve triage and infection control, but it does not revise the established pathogenic profile 41905499Mar.

Overview update candidates: method-focused diagnostic advances for K. pneumoniae detection; mechanistic clarification of IS26-mediated blaSHV-1 amplification in piperacillin-tazobactam resistance; nanoemulsion-based suppression of multidrug-resistant K. pneumoniae biofilm activity.